AC2993 28-Day Profile in Type 2 DiabetesPotent Glucose-Lowering with No Weight Gain

-3

0

3

*

• All subjects responded to AC2993

• No severe hypoglycemia observed

• Dose regimen established

• Adverse events reduced with dose escalation 

Additional Phase 2 observations

Placebo (N=28)

AC2993 BID (at breakfast and dinner) N=26

Note: 28-day results may underestimate total effect on HbA1c and body weight

* Statistically different from placebo

0

-0.4

-0.8

-1.2

*

? HbA1c (%)

? Body Weight (lb)

As reported at ADA in June 2001

Previous slide

Next slide

Back to first slide

View graphic version